<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04378010</url>
  </required_header>
  <id_info>
    <org_study_id>EDP 305-102</org_study_id>
    <nct_id>NCT04378010</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH</brief_title>
  <official_title>A Phase 2b Randomized, Double Blind, Placebo-Controlled, Multicenter Study Evaluating Safety and Efficacy of EDP-305 in Subjects With Liver Biopsy Proven Non-Alcoholic Steatohepatitis (NASH) (ARGON-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enanta Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Enanta Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind study to assess the safety and efficacy of EDP-305 in subjects
      with liver-biopsy proven Non-Alcoholic Steatohepatitis (NASH)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 27, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who achieve ≥1 stage improvement in fibrosis without worsening of steatohepatitis and/or resolution of steatohepatitis and no worsening of liver fibrosis as determined by liver biopsy</measure>
    <time_frame>Measurement at Week 72</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by adverse events</measure>
    <time_frame>Up to 72 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">336</enrollment>
  <condition>Non-Alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>EDP-305 1.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once a day orally for 72 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-305 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once a day orally for 72 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once a day orally for 72 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP-305 1.5 mg</intervention_name>
    <description>Tablet</description>
    <arm_group_label>EDP-305 1.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP-305 2 mg</intervention_name>
    <description>Tablet</description>
    <arm_group_label>EDP-305 2 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent documentation signed and dated by the subject.

          -  Male and female subjects, of all ethnic origins, between the ages of 18 and 75 years,
             inclusive.

          -  Subjects of all ethnic origins should have a Body Mass Index (BMI) &gt; 25 kg/m2 and ≥45
             except for Asian subjects who qualify for the study with BMI &gt; 23kg/m2.

          -  Histological evidence of definite NASH based on NASH Clinical Research Network (CRN)
             criteria obtained from assessment of a liver biopsy by the central histopathologist.
             The biopsy may be obtained either 1) during the Screening window or 2) within 6 months
             prior to the Screening visit.

          -  NAFLD Activity Score (NAS) of 4 or greater with a score of at least 1 in each
             component of the NAS (steatosis scored 0-3, lobular inflammation scored 0-3,
             ballooning scored 0-2).

          -  Fibrosis stage 2 or 3 using the NASH CRN Histologic Scoring System.

          -  Subjects must have Screening laboratory values for Hepatitis B surface antigen
             (HBsAg), anti-HCV antibodies and HCV RNA, and Human Immunodeficiency Virus (HIV) 1 and
             2 antibodies (Ab) as seronegative. [Note: subjects previously infected by chronic
             hepatitis C and treated with direct acting antivirals (DAAs) with sustained virologic
             response (SVR) for at least 3 years will be allowed.]

          -  A woman of childbearing potential who is sexually active with a male must agree to use
             two effective methods of contraception from the date of Screening until 30 days after
             the last dose of study drug.

          -  A male subject who has not had a vasectomy and is sexually active with a woman of
             childbearing potential must agree to use effective contraception from the date of
             Screening to 90 days after the last dose of study drug.

          -  Subject must be willing and able to adhere to the assessments, visit schedules,
             prohibitions and restrictions, as described in this protocol.

        Exclusion Criteria:

          -  Laboratory Screening results as indicated below:

               -  Total white blood cells (WBC) &lt;3000 cells/mm3

               -  Absolute neutrophil count (ANC) &lt;1500 cells/mm3

               -  Platelet count &lt;140,000/mm3

               -  International Normalized Ratio, INR &gt;1.2 (unless due to use of anticoagulants)

               -  Estimated glomerular filtration rate (eGFR) &lt; 60 mL/min according to the
                  Modification of Diet in Renal Disease (MDRD) equation

               -  AST ≥5× ULN

               -  ALT ≥5× ULN

               -  ALP ≥ 2x ULN

               -  Total bilirubin &gt; 1.5 times ULN during Screening. [Note: Patients with Gilbert's
                  syndrome will be allowed following review by the Medical Monitor if they have a
                  known history of Gilbert's syndrome with a normal direct bilirubin value and
                  normal reticulocyte count.]

          -  Pregnant or nursing females.

          -  MELD: Model for End-stage Liver Disease score &gt;12.

          -  Clinical or laboratory evidence of known chronic liver disease such as alcoholic liver
             disease, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC),
             autoimmune hepatitis, Wilson disease, iron overload, alpha-1-antitrypsin deficiency,
             drug-induced liver injury, known or suspected hepatocellular carcinoma (HCC).

          -  History of acute liver complications due to gallstones (e.g., acute cholecystitis or
             acute biliary obstruction) unless the subject has had a cholecytectomy (more than 3
             months prior to screening).

          -  History of liver transplant, or current placement on a liver transplant list.

          -  Hepatorenal syndrome (type I or II).

          -  Prior variceal hemorrhage, uncontrolled encephalopathy, liver cirrhosis Child-Pugh
             Class A, B, and C, esophageal varices, or refractory ascites within the previous 6
             months of Screening and/or histological presence of liver cirrhosis.

          -  Prior or planned ileal resection, or prior or planned bariatric surgery. [Note:
             Subjects who have undergone gastric surgeries that do not affect drug absorption
             (e.g., gastric band or gastric sleeve procedures) will be allowed if they are stable
             for at least 1 year prior to Screening. Gastrectomy or Roux-en-Y bypass will be
             allowed if stable for at least 3 years prior to Screening.]

          -  Subjects with clinically or otherwise documented cardiovascular or cerebrovascular
             disease including clinically significant anomalies of rhythm or pattern of ECG, that
             in the judgement of the Principal Investigator (PI) could affect the safety of the
             subject or their ability to comply with the study requirements.

          -  HbA1c ≥ 9.5% within 60 days prior to Day 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enanta Pharmaceuticals, Inc</last_name>
    <role>Study Director</role>
    <affiliation>Enanta Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Enanta Pharmaceuticals, Inc</last_name>
    <phone>617 607 0705</phone>
    <email>nadda@enanta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Liver Health</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Institute of Liver Health</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hope Clinical Research, LLC</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hessam Aazami</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>eStudy Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southern California Research Center</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ADVA Clinical Research</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanuel Sima</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>eStudySite - La Mesa</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inland Empire Liver Foundation</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southern California Gastrointestinal and Liver Centers</name>
      <address>
        <city>San Clemente</city>
        <state>California</state>
        <zip>92673</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Precision Research Institute, Llc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universal Axon Clinical Research</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Martinez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westside Center for Clinical Research</name>
      <address>
        <city>Fleming Island</city>
        <state>Florida</state>
        <zip>32003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nature Coast Clinical Research</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Westside Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Braddock</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Encore Borland Groover Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Maria Corregidor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva-Maria Heurich</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Marcus Research Clinic, Inc.</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Veritas Research Corp</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Robaina</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Associates of South Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ocala GI Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Digestive Research Alliance of Michiana</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46635</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Associates, PA</name>
      <address>
        <city>Catonsville</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mid-Atlantic GI Research</name>
      <address>
        <city>Greenbelt</city>
        <state>Maryland</state>
        <zip>20770</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raja Mohi-ud-din</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern Therapy and Advanced Research LLC GI Associates and Endoscopy Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Borg</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AGA Clinical Research Associates, LLC</name>
      <address>
        <city>Egg Harbor Township</city>
        <state>New Jersey</state>
        <zip>08234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northeast GI Research Division</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>28027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lucas Research</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Jean Lucas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Digestive Health Research, LLC</name>
      <address>
        <city>Hermitage</city>
        <state>Tennessee</state>
        <zip>37076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Lazas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Digestive Health Research</name>
      <address>
        <city>Lebanon</city>
        <state>Tennessee</state>
        <zip>37090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jocelyne Miller</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quality Medical Research</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Herring</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Clinical Research Institute</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reem Ghalib</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Diabetes &amp; Endocrinology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78749</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsay Harrison</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>DHAT Research Institute</name>
      <address>
        <city>Garland</city>
        <state>Texas</state>
        <zip>75044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harry E Sarles</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>American Research Corporation at The Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Lawitz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas S Denham</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bon Secours St. Mary's Hospital of Richmond, Inc</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell Shiffman</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2020</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fatty Liver, non-alcoholic fatty liver disease, liver diseases, Digestive system diseases, NASH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

